Elicio Therapeutics Inc. (ELTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Elicio Therapeutics Inc. stock (ELTX) is currently trading at $10.96. Analyst consensus price target for ELTX is $17.50. WallStSmart rates ELTX as Sell.
- ELTX PE ratio analysis and historical PE chart
- ELTX PS ratio (Price-to-Sales) history and trend
- ELTX intrinsic value — DCF, Graham Number, EPV models
- ELTX stock price prediction 2025 2026 2027 2028 2029 2030
- ELTX fair value vs current price
- ELTX insider transactions and insider buying
- Is ELTX undervalued or overvalued?
- Elicio Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- ELTX Piotroski F-Score and Altman Z-Score
- ELTX analyst price target and Smart Rating
Elicio Therapeutics Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Elicio Therapeutics Inc. (ELTX) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Elicio Therapeutics Inc. (ELTX) Key Strengths (0)
Supporting Valuation Data
Elicio Therapeutics Inc. (ELTX) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 122.0x book value
Very low institutional interest at 12.63%
Micro-cap company with very limited liquidity and high volatility
Elicio Therapeutics Inc. (ELTX) Detailed Analysis Report
Overall Assessment
This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (122.00) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -60013.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60013.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ELTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ELTX's Price-to-Sales ratio of 7.16x trades at a deep discount to its historical average of 14.4x (82th percentile). The current valuation is 93% below its historical high of 108.89x set in Mar 2021, and 1945% above its historical low of 0.35x in Mar 2023. Over the past 12 months, the PS ratio has expanded from ~4.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Elicio Therapeutics Inc. (ELTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Elicio Therapeutics Inc. operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.68, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Elicio Therapeutics Inc..
Bottom Line
Elicio Therapeutics Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:26:27 AM
About Elicio Therapeutics Inc.(ELTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Elicio Therapeutics Inc. (ELTX) is a pioneering clinical-stage biotechnology company dedicated to revolutionizing cancer treatment through its innovative immunotherapies. Leveraging its proprietary Amphiphilic TLR9 Agonist (Eli-002), the company aims to elicit robust immune responses across a spectrum of cancer types, enhancing patient outcomes significantly. Elicio's strategic focus on personalized cancer vaccines and advanced immunotherapeutic approaches positions it to meet critical unmet medical needs in oncology, with ongoing clinical trials that underscore its commitment to transforming cancer care.